Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis

Experience of a single institution

Victor H. Jimenez-Zepeda, Norman Franke, Donna E. Reece, Suzanne Trudel, Christine Chen, Diego H. Delgado, Andrew Winter, Joseph R Mikhael, Rodger Tiedemann, Vishal Kukreti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Summary: Autologous stem-cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant-related mortality rates are high, and a recent randomized trial suggested that non-transplant regimens produced comparable results with less toxicity. In order to define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive AL amyloidosis patients transplanted at our centre. Transplant-related mortality occurred in 11·5%. Complete haematological response and organ response were achieved in 56% and 60%. Median overall survival was significantly lower for patients with brain-type natriuretic peptide (BNP) >300 pg/ml (17·5 months vs. not-reached) (P = 0·0004), troponin-I >0·07 ng/ml (13·5 months vs. not-reached) (P = 0·00001) and those not achieving a complete haematological response (88 months vs. not-reached) (P = 0·0345); high BNP and troponin-I were the most important predictive factors in a multivariate analysis. Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin-I should be considered transplant candidates.

Original languageEnglish (US)
Pages (from-to)722-728
Number of pages7
JournalBritish Journal of Haematology
Volume164
Issue number5
DOIs
StatePublished - Mar 2014

Fingerprint

Amyloidosis
Troponin I
Brain Natriuretic Peptide
Stem Cells
Transplants
Mortality
Stem Cell Transplantation
Therapeutics
Patient Selection
Multivariate Analysis
Survival

Keywords

  • Brain natriuretic peptide
  • High-dose melphalan
  • Light-chain amyloidosis
  • Transplantation
  • Troponin I

ASJC Scopus subject areas

  • Hematology

Cite this

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis : Experience of a single institution. / Jimenez-Zepeda, Victor H.; Franke, Norman; Reece, Donna E.; Trudel, Suzanne; Chen, Christine; Delgado, Diego H.; Winter, Andrew; Mikhael, Joseph R; Tiedemann, Rodger; Kukreti, Vishal.

In: British Journal of Haematology, Vol. 164, No. 5, 03.2014, p. 722-728.

Research output: Contribution to journalArticle

Jimenez-Zepeda, VH, Franke, N, Reece, DE, Trudel, S, Chen, C, Delgado, DH, Winter, A, Mikhael, JR, Tiedemann, R & Kukreti, V 2014, 'Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: Experience of a single institution', British Journal of Haematology, vol. 164, no. 5, pp. 722-728. https://doi.org/10.1111/bjh.12673
Jimenez-Zepeda, Victor H. ; Franke, Norman ; Reece, Donna E. ; Trudel, Suzanne ; Chen, Christine ; Delgado, Diego H. ; Winter, Andrew ; Mikhael, Joseph R ; Tiedemann, Rodger ; Kukreti, Vishal. / Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis : Experience of a single institution. In: British Journal of Haematology. 2014 ; Vol. 164, No. 5. pp. 722-728.
@article{0e706b34e5aa45ceb268c042c25aee42,
title = "Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: Experience of a single institution",
abstract = "Summary: Autologous stem-cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant-related mortality rates are high, and a recent randomized trial suggested that non-transplant regimens produced comparable results with less toxicity. In order to define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive AL amyloidosis patients transplanted at our centre. Transplant-related mortality occurred in 11·5{\%}. Complete haematological response and organ response were achieved in 56{\%} and 60{\%}. Median overall survival was significantly lower for patients with brain-type natriuretic peptide (BNP) >300 pg/ml (17·5 months vs. not-reached) (P = 0·0004), troponin-I >0·07 ng/ml (13·5 months vs. not-reached) (P = 0·00001) and those not achieving a complete haematological response (88 months vs. not-reached) (P = 0·0345); high BNP and troponin-I were the most important predictive factors in a multivariate analysis. Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin-I should be considered transplant candidates.",
keywords = "Brain natriuretic peptide, High-dose melphalan, Light-chain amyloidosis, Transplantation, Troponin I",
author = "Jimenez-Zepeda, {Victor H.} and Norman Franke and Reece, {Donna E.} and Suzanne Trudel and Christine Chen and Delgado, {Diego H.} and Andrew Winter and Mikhael, {Joseph R} and Rodger Tiedemann and Vishal Kukreti",
year = "2014",
month = "3",
doi = "10.1111/bjh.12673",
language = "English (US)",
volume = "164",
pages = "722--728",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis

T2 - Experience of a single institution

AU - Jimenez-Zepeda, Victor H.

AU - Franke, Norman

AU - Reece, Donna E.

AU - Trudel, Suzanne

AU - Chen, Christine

AU - Delgado, Diego H.

AU - Winter, Andrew

AU - Mikhael, Joseph R

AU - Tiedemann, Rodger

AU - Kukreti, Vishal

PY - 2014/3

Y1 - 2014/3

N2 - Summary: Autologous stem-cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant-related mortality rates are high, and a recent randomized trial suggested that non-transplant regimens produced comparable results with less toxicity. In order to define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive AL amyloidosis patients transplanted at our centre. Transplant-related mortality occurred in 11·5%. Complete haematological response and organ response were achieved in 56% and 60%. Median overall survival was significantly lower for patients with brain-type natriuretic peptide (BNP) >300 pg/ml (17·5 months vs. not-reached) (P = 0·0004), troponin-I >0·07 ng/ml (13·5 months vs. not-reached) (P = 0·00001) and those not achieving a complete haematological response (88 months vs. not-reached) (P = 0·0345); high BNP and troponin-I were the most important predictive factors in a multivariate analysis. Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin-I should be considered transplant candidates.

AB - Summary: Autologous stem-cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant-related mortality rates are high, and a recent randomized trial suggested that non-transplant regimens produced comparable results with less toxicity. In order to define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive AL amyloidosis patients transplanted at our centre. Transplant-related mortality occurred in 11·5%. Complete haematological response and organ response were achieved in 56% and 60%. Median overall survival was significantly lower for patients with brain-type natriuretic peptide (BNP) >300 pg/ml (17·5 months vs. not-reached) (P = 0·0004), troponin-I >0·07 ng/ml (13·5 months vs. not-reached) (P = 0·00001) and those not achieving a complete haematological response (88 months vs. not-reached) (P = 0·0345); high BNP and troponin-I were the most important predictive factors in a multivariate analysis. Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin-I should be considered transplant candidates.

KW - Brain natriuretic peptide

KW - High-dose melphalan

KW - Light-chain amyloidosis

KW - Transplantation

KW - Troponin I

UR - http://www.scopus.com/inward/record.url?scp=84894061446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894061446&partnerID=8YFLogxK

U2 - 10.1111/bjh.12673

DO - 10.1111/bjh.12673

M3 - Article

VL - 164

SP - 722

EP - 728

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -